Tessera Therapeutics vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Tessera Therapeutics is developing Gene Writing technology to insert large therapeutic sequences directly into the genome without double-strand DNA breaks; raised $230M+ including a $100M Series B;
About
Tessera Therapeutics is a genomic medicine company founded in 2018 by Jacob Rubens, Brian Goodman, and colleagues at Flagship Pioneering (the life sciences venture creation firm behind Moderna) and headquartered in Cambridge, Massachusetts. The company is pioneering Gene Writing — a platform technology that uses mobile genetic elements (specifically RNA-guided integrases derived from retrotransposons) to write large DNA sequences directly into the human genome at targeted sites, without requiring double-strand DNA breaks. This approach is designed to overcome key limitations of first-generation gene editing technologies: CRISPR-Cas9 creates double-strand breaks that can introduce unintended mutations, and current gene editing tools are largely limited to small sequence corrections or knockouts rather than full gene insertions.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Tessera Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.